We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · August 13, 2019

Stereotactic Ablative Radiotherapy Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer

International Journal of Radiation Oncology*Biology*Physics

 

Additional Info

International Journal of Radiation Oncology*Biology*Physics
Stereotactic Ablative Radiotherapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer
Int. J. Radiat. Oncol. Biol. Phys 2019 Jul 29;[EPub Ahead of Print], Y Zhang, J Schoenhals, A Christie, O Mohamad, C Wang, I Bowman, N Singla, H Hammers, K Courtney, A Bagrodia, V Margulis, N Desai, A Garant, H Choy, J Brugarolas, R Timmerman, R Hannan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.


Further Reading